XML 62 R36.htm IDEA: XBRL DOCUMENT v3.25.4
Stock-based Compensation (Tables)
12 Months Ended
Dec. 31, 2025
Share-Based Payment Arrangement [Abstract]  
Schedule of Black-Scholes Option Pricing Model Assumptions The following table presents 1) assumptions used in the Black-Scholes option pricing model to determine the estimated grant date fair
values of stock options and SARS granted to employees; and 2) options and SARS granted and weighted average grant date fair value.
 
Years Ended December 31,
 
2025
2024
2023
(Shares in thousands)
Weighted average expected life (years)
4.2
4.0
9.1
Weighted average expected volatility
50.5%
49.0%
60.4%
Risk-free interest rate
3.50%4.13%
3.52%4.54%
3.87%3.87%
Weighted average dividend yield
—%
—%
—%
Stock options and SARS granted
144
721
14
Weighted average grant date fair value
$6.08
$6.36
$8.72
Schedule of Forfeiture Rates The following table presents the estimated weighted average forfeiture rates for all employees used in determining the expense in the
stock-based compensation expense table above.
 
Years Ended December 31,
 
2025
2024
2023
Stock options, SARS, RSUs and PRSUs
6.4%
6.3%
6.4%
Schedule of Share-based Compensation Expense The following table presents the stock-based compensation expense related to the fair value measurement of awards granted to
employees by expense category and by type of award.  All stock-based payment awards are amortized on a straight-line basis over the
requisite service periods of the awards.
 
Years Ended December 31,
 
2025
2024
2023
(In thousands)
Stock-based compensation expense charged to:
Cost of revenue
$543
$1,076
$719
General and administrative
3,307
4,013
3,661
Sales and marketing
2,859
3,489
2,333
Research and development
1,010
1,744
1,325
Total stock-based compensation expense
$7,719
$10,322
$8,038
Stock-based compensation expense by type of award:
Stock options and SARS
$1,502
$2,334
$1,985
RSUs
6,217
7,988
6,053
Total stock-based compensation expense
$7,719
$10,322
$8,038
Schedule of Stock Option Activity The following table presents stock option and SARS activities under the Equity Incentive Plans.
 
Number of
Shares
Weighted
Average
Exercise Price
Weighted
Average
Remaining
Contractual
Life
Aggregate
Intrinsic
Value(1)
(In thousands)
(Per share)
(In years)
(In thousands)
Balance, December 31, 2022
2,421
$11.02
Granted
14
22.13
Exercised
(511)
9.38
$5,619
Balance, December 31, 2023
1,924
11.54
Granted
721
15.02
Exercised
(767)
9.26
5,260
Forfeited
(270)
18.06
Balance, December 31, 2024
1,608
13.09
Granted
144
14.74
Exercised
(269)
8.93
1,664
Forfeited
(86)
15.49
Balance, December 31, 2025
1,397
$13.91
6.5
$1,758
Vested and exercisable as of December 31, 2025
839
$13.18
5.0
$1,671
Vested and exercisable as of December 31, 2025 and expected to vest thereafter
1,345
$13.87
6.4
$1,750
(1)The aggregate intrinsic value of an exercised option and SARS is calculated as the difference between the exercise price of the underlying option and
SARS and the fair value of the Company’s common stock at the time of exercise.  The aggregate intrinsic value at December 31, 2025 is calculated as
the difference between the exercise price of the underlying outstanding options and SARS and the fair value of the Company’s common stock as of
December 31, 2025 or the last trading day prior to December 31, 2025.
Schedule of Restricted Stock Units Activity The following table presents RSU activities under the Equity Incentive Plans.
 
Number of
Shares
Weighted
Average
Grant Date
Fair Value
(In thousands)
(Per share)
Balance, December 31, 2022
688
$15.51
Awarded
546
23.97
Vested
(294)
14.02
Forfeited
(21)
19.91
Balance, December 31, 2023
919
20.91
Awarded
751
14.85
Vested
(389)
18.79
Forfeited
(281)
20.70
Balance, December 31, 2024
1,000
17.24
Awarded
707
14.48
Vested
(367)
17.34
Forfeited
(277)
16.55
Balance, December 31, 2025
1,063
15.56
The following table presents PRSU activities under the Equity Incentive Plans.
 
Number of
Shares
Weighted
Average
Grant Date
Fair Value
(In thousands)
(Per share)
Balance, December 31, 2024
$
Awarded
305
14.69
Vested
Forfeited
(23)
15.05
Balance, December 31, 2025
281
14.66
Schedule of Vested Stock Options and RSUs The following table presents the total grant date fair value of equity awards vested during the period.
Years Ended December 31,
2025
2024
2023
(In thousands)
Stock options and SARs
$1,991
$857
$2,724
RSUs
6,365
7,298
4,112
PRSUs
Total grant date fair value of equity awards vested during the period
$8,356
$8,155
$6,836
Schedule of Unamortized Compensation Cost and Weighted Average Service Period The following table presents the unamortized compensation costs and weighted average
service period of all unvested outstanding awards as of December 31, 2025.
Unamortized
Compensation
Costs
Weighted Average
Service Period
(In thousands)
(In years)
Stock options and SARs
$2,922
2.0
RSUs
10,079
1.3
PRSUs
3,158
2.0
Total unamortized compensation costs, net of adjusted forfeitures
$16,159